Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis.

[1]  Minetta C. Liu,et al.  Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer. , 2023, Journal of Clinical Oncology.

[2]  A. Laenen,et al.  Survival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma , 2022, JAMA network open.

[3]  J. Tabernero,et al.  Circulating tumor DNA as a novel prognostic indicator , 2022, Nature Medicine.

[4]  A. Miyamoto,et al.  Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy , 2021, Annals of Surgical Oncology.

[5]  P. Hegyi,et al.  Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis. , 2021, Critical reviews in oncology/hematology.

[6]  N. Tomita,et al.  The Conventional Technique Versus the No-touch Isolation Technique for Primary Tumor Resection in Patients With Colon Cancer (JCOG1006) , 2021, Annals of surgery.

[7]  S. Pavlovic,et al.  Meta-Analysis of Circulating Cell-Free DNA’s Role in the Prognosis of Pancreatic Cancer , 2021, Cancers.

[8]  L. Qin,et al.  Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways , 2021, Molecular Biomedicine.

[9]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Shinya Takahashi,et al.  Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma , 2020, Annals of Surgical Oncology.

[11]  E. Mayo-Wilson,et al.  PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews , 2020, BMJ.

[12]  X. Yi,et al.  Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer , 2020, Frontiers in Oncology.

[13]  C. Andersen,et al.  The effect of surgical trauma on circulating free DNA levels in cancer patients—implications for studies of circulating tumor DNA , 2020, Molecular oncology.

[14]  T. Rikiyama,et al.  Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer , 2019, PloS one.

[15]  K. Kinzler,et al.  Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localised pancreatic cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  T. Peretz,et al.  Life and death of circulating cell-free DNA , 2019, Cancer biology & therapy.

[17]  Richard D Riley,et al.  A guide to systematic review and meta-analysis of prognostic factor studies , 2019, British Medical Journal.

[18]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[19]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[20]  Xuelei Ma,et al.  Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis. , 2018, Gene.

[21]  M. Bijlsma,et al.  The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma , 2018, Molecular Cancer.

[22]  W. Xu,et al.  Diagnostic and prognostic value of KRAS mutations in circulating pancreatic ductal adenocarcinoma tumor DNA , 2018, Translational Cancer Research.

[23]  J. Kleeff,et al.  Therapeutic developments in pancreatic cancer: current and future perspectives , 2018, Nature Reviews Gastroenterology & Hepatology.

[24]  T. Hibi,et al.  KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study , 2018, British Journal of Cancer.

[25]  Shuai Huang,et al.  Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review , 2017, BioMed research international.

[26]  I. Bièche,et al.  Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know? , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  J. Hayden,et al.  Adjuvant therapy for resected pancreatic cancer , 2017 .

[28]  Stefan Sleijfer,et al.  Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions , 2017, Molecular oncology.

[29]  S. Merajver,et al.  Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. , 2016, Clinical biochemistry.

[30]  P. B. Gahan,et al.  Origins, structures, and functions of circulating DNA in oncology , 2016, Cancer and Metastasis Reviews.

[31]  E. Hiyama,et al.  Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer , 2016, British Journal of Cancer.

[32]  D. Jäger,et al.  Pancreatic Cancer Surgery: The New R-status Counts , 2016, Annals of surgery.

[33]  R. Andersson,et al.  Pancreatic cancer: yesterday, today and tomorrow. , 2016, Future oncology.

[34]  H. Ueno,et al.  Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer , 2015, Scientific Reports.

[35]  J. Kench,et al.  Meta‐analysis of radical resection rates and margin assessment in pancreatic cancer , 2015, The British journal of surgery.

[36]  R. Scharpf,et al.  Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients , 2015, Nature Communications.

[37]  K. Nouso,et al.  Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer , 2015, Cancer.

[38]  W. Fisher,et al.  Pancreatic cancer: advances in treatment. , 2014, World journal of gastroenterology.

[39]  S. Gill,et al.  Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis , 2014, BMC Cancer.

[40]  J. Jacob,et al.  Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. , 2014, JAMA surgery.

[41]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[42]  C. Bombardier,et al.  Assessing Bias in Studies of Prognostic Factors , 2013, Annals of Internal Medicine.

[43]  J. Wind,et al.  Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[44]  M. Ogawa,et al.  Pancreatectomy using the no-touch isolation technique followed by extensive intraoperative peritoneal lavage to prevent cancer cell dissemination: a pilot study. , 2005, JOP : Journal of the pancreas.

[45]  D. Lorenz,et al.  Long-term Results of Partial Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreatic Head: 25-Year Experience , 2003, World Journal of Surgery.

[46]  H. Egami,et al.  No-touch isolation technique reduces intraoperative shedding of tumor cells into the portal vein during resection of colorectal cancer. , 1999, Surgery.

[47]  M Monden,et al.  Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  S. Nomoto,et al.  Detection of ras Gene Mutations in Perioperative Peripheral Blood with Pancreatic Adenocarcinoma , 1996, Japanese journal of cancer research : Gann.

[49]  T. Colby,et al.  Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving? , 1995, Annals of surgery.

[50]  J. Arends,et al.  No‐Touch isolation technique in colon cancer: A controlled prospective trial , 1988, The British journal of surgery.

[51]  F. R. Watson,et al.  Cancer of the colon: the influence of the no-touch isolation technic on survival rates. , 1967, Annals of surgery.

[52]  S. Srivastava,et al.  STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. , 2015, Carcinogenesis.

[53]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[54]  A. Gilmore,et al.  Anoikis. , 2000, Cell death and differentiation.